Navigation Links
Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma
Date:12/8/2008

SAN FRANCISCO, Dec. 8 /PRNewswire/ -- Millennium: The Takeda Oncology Company today reported updated results based on extended follow up of patients from the large, international Phase III VISTA(1) trial showing continued survival improvement for patients with previously untreated multiple myeloma given VELCADE, melphalan and prednisone (VcMP). The VELCADE combination demonstrated consistent efficacy in all patient sub-groups, including those with poor prognostic characteristics, such as advanced age, poor risk cytogenetics and renal impairment. These data were presented at the 50th Annual Meeting of the American Society of Hematology (ASH), held December 5-9, 2008 in San Francisco, California.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080827/NEW076LOGO )

"The ultimate goal in treating multiple myeloma is to prolong the patient's life," said Professor Jesus San-Miguel, M.D., Ph.D., Hospital Universitario de Salamanca and Principal Investigator of the trial. "The follow-up data from the VISTA study showed that the addition of VELCADE to melphalan and prednisone continued to demonstrate a long-term survival advantage for patients with previously untreated multiple myeloma."

The VISTA trial enrolled 682 patients with previously untreated multiple myeloma ineligible for stem cell transplantation. The first interim analysis was presented at ASH 2007. Data with a median follow up of 25.9 months were presented at this year's ASH meeting. In addition, a detailed analysis evaluated the impact of subsequent therapy on the overall survival (OS) results. The updated results, which were presented by Professor San-Miguel, included:

  • Thirty-six percent reduced risk of death in the VcMP arm, compared with the MP arm (hazard ratio =0.644, p=0.0032; median survival not yet reached in either a
    '/>"/>

SOURCE Millennium: The Takeda Oncology Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
2. FDA Advisory Committees Recommend Continued U.S. Marketing Authorization for Trasylol(R)
3. Facet Solutions Enjoys Continued Clinical Success With the Anatomic Facet Replacement System (AFRS(TM))
4. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
5. Raven Announces Continued Enrollment of Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
6. New Trial Presented at AAAAI Reports that the Growth of Children 2-5 Years Old with Year-Round Allergic Rhinitis Continued According to Normal Age-Adjusted Distribution Over a 6-Month Treatment with Nasacort AQ
7. Continued Funding to Help Advance Exciting Moment in Diabetes Research
8. Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial
9. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
10. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
11. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 28, 2015  Today, in final recognition of the ... Health Week, 1-800 Contacts is sharing how to keep ... lens wearers who do not properly care for their ... infections. Most contact lens wearers understand ... clean lens case is sometimes overlooked.  When proper steps ...
(Date:8/28/2015)... Aug. 28, 2015 ... the addition of the "Investigation Report on ... offering. Developed by AstraZeneca plc, quetiapine ... important drug for the treatment of schizophrenia. Approved ... was listed in the Catalogue of Drugs for ...
(Date:8/28/2015)... Aug. 28, 2015 ... the addition of the "Investigation Report on ... offering. Developed by Pharmacia & Upjohn ... agonist which effectively reduces intraocular pressure. As the ... (under the trade name of Xalatan) entered ...
Breaking Medicine Technology:1-800 Contacts Shares Tips on How to Clean Lens Cases 2China Quetiapine Market Investigation Report 2010-2019 2China Latanoprost Market Investigation Report 2015-2019 2
... the novel,selective relaxant binding agent (SRBA) being developed ... neuromuscular blockade as,compared to neostigmine in the Phase ... Spectrum, faster recovery from profound neuromuscular,blockade compared to ... were presented today at the 2007 annual meeting ...
... safety of nebulized,formoterol fumarate and safety/ efficacy of concomitant use with ... ... 16 Dey, L.P., a subsidiary of Mylan,Inc. (NYSE: MYL ... the annual scientific assembly of the American College of,Chest Physicians (ACCP) ...
Cached Medicine Technology:Sugammadex Trials Demonstrate Rapid Recovery from Profound Neuromuscular Blockade During General Anesthesia 2Sugammadex Trials Demonstrate Rapid Recovery from Profound Neuromuscular Blockade During General Anesthesia 3Sugammadex Trials Demonstrate Rapid Recovery from Profound Neuromuscular Blockade During General Anesthesia 4Sugammadex Trials Demonstrate Rapid Recovery from Profound Neuromuscular Blockade During General Anesthesia 5Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007 2Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007 3Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007 4Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007 5
(Date:8/29/2015)... ... August 29, 2015 , ... It can ... protection against dribbled urine and sweat. "In order to prevent these problems, I ... EASY ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides optimal support for a male’s crotch. ...
(Date:8/29/2015)... ... 2015 , ... Next weekend is Labor Day weekend, the last bash of ... 22nd this year). For IT security personnel, it should also mark the perfect time ... more costly than a simple headache. , Joe Caruso, founder and CEO-CTO of ...
(Date:8/29/2015)... ... , ... The popular television program VOICES IN AMERICA, hosted by legendary star ... devoting an entire short segment to the subject of diabetes. Diabetes is a debilitating ... daily basis, but recent advancements in medical science may prove to be a significant ...
(Date:8/28/2015)... , ... August 28, 2015 , ... An online provider ... to make the purchase of CPAP equipment more affordable by offering shipping at no ... types of CPAP products and orders of any size. My Cpap Store is located ...
(Date:8/28/2015)... , ... August 28, 2015 , ... With the goal ... returned for the second year to the Adams County Fairgrounds in Mendon, IL on ... to raise money to support music education in the underfunded school districts of Mendon ...
Breaking Medicine News(10 mins):Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:My Cpap Store Now Offering Delivery Special 0 Cost to You 2Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2
... Wis., Oct. 9 October marks National,Domestic Violence ... people,in the United States are affected by domestic ... American Academy of Cosmetic Dentistry,Charitable Foundation,s (AACDCF) Give ... to "restore a life by restoring a smile" ...
... in risk, study found , , TUESDAY, Oct. 9 (HealthDay News) ... could cut their odds for deadly ovarian cancer, new research ... regimen for more than eight years reduced their risk for ... who saw the greatest benefit from the low-fat diet were ...
... Researchers at the University of Pennsylvania School of Medicine ... degeneration (AMD) caused by a mutation known to produce ... treatments. The study appears in the October issue of ... the most common cause of vision loss in elderly ...
... Pantoliano,reveals a personal history of depression and his ... in a guest blog entry, http://www.nami.org/blog published ... Pantoliano,s entry comes during Mental Illness Awareness ... opening of his latest film, CANVAS, http://www.canvasthefilm.com ...
... mouse study shows , TUESDAY, Oct. 9 (HealthDay News) ... may lead to a treatment for the hereditary, progressive ... mice, a molecule called C2-8 appears to reduce HD-related ... said the team from the MassGeneral Institute for Neurological ...
... recurrent heart attack risk, study finds , , TUESDAY, Oct. 9 ... someone who has had a heart attack will have another ... have shown that workplace stress boosts heart woes, but this ... attacks and other major events, the report,s authors said. , ...
Cached Medicine News:Health News:600 Smiles Restored Thanks to the AACDCF's Give Back A Smile Program - October Marks National Domestic Violence Awareness Month 2Health News:More Fiber, Less Fat Help Prevent Ovarian Cancer 2Health News:More Fiber, Less Fat Help Prevent Ovarian Cancer 3Health News:More Fiber, Less Fat Help Prevent Ovarian Cancer 4Health News:Model to study age-related macular degeneration could pave way for better treatment 2Health News:Actor Joe Pantoliano Discloses Depression; Talks About His Latest Movie and His Sensitive Side 2Health News:Molecule Promising Against Huntington's Disease 2Health News:Stressful Jobs Hard on the Heart 2Health News:Stressful Jobs Hard on the Heart 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: